Stressgen (VSE: SSB) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Stressgen (VSE: SSB)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Heat Shock who wrote (134)	9/11/2000 5:18:58 PM
From: Heat Shock	of 236

To all: StressGen initiates HspE7 Phase II Trial in cervical cancer The broad attack of clinical trials marches on. Heat Shock Fusion Protein - A Novel Therapeutic for HPV-Related Diseases VICTORIA, BC, Sept. 6 /PRNewswire/ - StressGen Biotechnologies Corp. (TSE: SSB - news) announced today that it has initiated patient treatment in its Phase II clinical trial to investigate HspE7, a novel immunotherapeutic, as a treatment for advanced cancer of the uterine cervix caused by the human papillomavirus (HPV). This disease is associated with extreme morbidity and is always fatal when surgery and radiotherapy fail. biz.yahoo.com Heat.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next